Abstract:Background: We report on a patient with a branch retinal artery occlusion (RAO) and its recanalization based on multimodal retinal and angiographic images after he was administered the first dose of the SARS-CoV-2 mRNA vaccine.Case summary: A 64-year-old man complained of a right, painless, inferior field defect 3 days after the first dose of BNT162b2 vaccination. Fundus examination revealed decolorization of the right upper macula, including microthrombi in the superior proximal branch of the retinal artery. … Show more
“…ACVS and PACVS) have been published yet but corresponding observations have already been made during medical examinations (Beate R. Jaeger, personal communication). Microthrombi were detected in biopsies of tissue in case of COVID-19 [390] , [391] , [392] , [393] and PCVS (in general in the case of VITT) [394] , [395] , [396] , [397] , [398] , [399] , [400] , [401] , [402] . Fig.…”
Section: Sars-cov-2 Infection- and Covid-19 Vaccination-induced Syndr...mentioning
“…ACVS and PACVS) have been published yet but corresponding observations have already been made during medical examinations (Beate R. Jaeger, personal communication). Microthrombi were detected in biopsies of tissue in case of COVID-19 [390] , [391] , [392] , [393] and PCVS (in general in the case of VITT) [394] , [395] , [396] , [397] , [398] , [399] , [400] , [401] , [402] . Fig.…”
Section: Sars-cov-2 Infection- and Covid-19 Vaccination-induced Syndr...mentioning
“…Two patients with retinal ischemic events after application of the Moderna vaccine (MOV) respectively the Johnson & Johnson vaccine (JJV) have been recently reported 6 . Kang et al reported a 64yo male who experienced a branch retinal artery occlusion three days after the first dose of the Biontech Pfizer vaccine (BPV) 7 . A 76yo female developed unilateral, painless visual loss 2 days after the first dose of the AZV 8 .…”
“…The interval was 1 day for one patient diagnosed with branch retinal arterial occlusion, and shorter than 1 day for two patients diagnosed with central retinal arterial occlusion and vitreous hemorrhage, respectively. Retinal arterial occlusion has been previously reported after vaccination with the mRNA COVID-19 vaccine, and were characterized by non-embolic, not accompanied by carotid plague or stenosis, rapid development within 2 weeks after vaccination, and without marked abnormalities of laboratory tests (such as increased D-dimer and C-reactive protein) [7]. The mean age of patients diagnosed with retinal vascular occlusion in the present study was 53 years, which was comparable to that of patients diagnosed with retinal vascular occlusion not associated with vaccination (53 years old) [25].…”
Section: Discussionmentioning
confidence: 87%
“…Inactivated COVID-19 vaccines have been widely used among the Chinese population and have shown good safety, tolerability, and immunogenicity [3,4]. Nevertheless, ocular adverse events have rarely been reported after COVID-19 mRNA vaccines, vector vaccines, and inactivated vaccines [5][6][7]. A relationship has not be established between reported ocular disorders and COVID-19 vaccines, because of limited awareness of the clinical spectrum of potential ocular adverse events, and unclear mechanisms for ocular disorders and COVID-19 vaccines.…”
Purpose: To report the clinical characteristics of ocular adverse events that have occurred, in China, after vaccination with inactivated COVID-19 vaccines. Methods: A retrospective cross-sectional observational study was conducted of ocular disorders that occurred within 15 days from any dose of an inactivated COVID-19 vaccine. Information on gender, age, the interval between the vaccination and ocular symptoms, laterality, duration of the ocular symptoms, primary visual acuity, and clinical diagnosis were retrospectively collected. Results: Twenty-four patients were involved in the study, including 15 females and 9 males, with a mean age of 41 ± 16 years (range of 8–71 years). The patients all denied a prior history of COVID-19 infection. Ocular adverse events occurred after the first dose of vaccine in 18 patients and, after the second or third doses, in six patients. The interval between vaccination with the inactivated COVID-19 vaccine and ocular symptoms was 6 ± 5 days; six patients were bilaterally involved and 18 patients were unilaterally involved. Regarding the diagnosis, 10 patients were diagnosed with white dot syndrome (WDS), 9 patients were diagnosed with uveitis, and 5 patients were diagnosed with retinal vascular disorders. The ages of patients with WDS were younger than those with uveitis or retinal vascular disorders (32 ± 10 vs. 48 ± 18, p < 0.05). For patients diagnosed with WDS, the best-corrected visual acuity (BCVA) was 0.74 ± 0.73 LogMAR. For patients diagnosed with retinal vascular disorders or uveitis, the BCVA was 1.44 ± 1.26 LogMAR. There was no significant difference (p > 0.05). Conclusions: A relationship cannot be established between inactivated COVID-19 vaccines and ocular disorders; therefore, further investigation of the clinical spectrum of ocular adverse events after vaccination with an inactivated COVID-19 vaccine is necessary.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
